These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 24670522)

  • 1. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
    Linas BP; Barter DM; Leff JA; DiLorenzo M; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Kim AY; Freedberg KA
    AIDS; 2014 Jan; 28(3):365-76. PubMed ID: 24670522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
    Blázquez-Pérez A; San Miguel R; Mar J
    Pharmacoeconomics; 2013 Oct; 31(10):919-31. PubMed ID: 24000086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
    Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
    J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study.
    Kurniawan J; Gani RA; Djauzi S; Ibrahim F; Harimurti K; Nafrialdi N; Imannuel S
    Acta Med Indones; 2019 Apr; 51(2):128-136. PubMed ID: 31383827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.
    Linas BP; Wong AY; Schackman BR; Kim AY; Freedberg KA
    Clin Infect Dis; 2012 Jul; 55(2):279-90. PubMed ID: 22491339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
    Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
    PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan.
    Igarashi A; Furusyo N; Ogawa E; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J
    BMJ Open; 2019 Jun; 9(6):e023405. PubMed ID: 31221866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.
    De Leon LB; Tovo CV; Kliemann DA; De Mattos AA; Feltrin AA; Pacheco LS; De Almeida PR
    J Infect Dev Ctries; 2016 Aug; 10(7):762-9. PubMed ID: 27482809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
    Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
    J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    Elbasha E; Greaves W; Roth D; Nwankwo C
    J Viral Hepat; 2017 Apr; 24(4):268-279. PubMed ID: 27966249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.